All Stories

  1. Association Between Reporting Antimicrobial Use and Clostridioides difficile Standardized Infection Ratios in South Carolina Hospitals
  2. Appropriateness of ambulatory antibiotic prescribing in South Carolina, 2012–2017
  3. Oral switch antibiotic therapy in uncomplicated Enterococcus faecalis bloodstream infection
  4. Missed Opportunities for Early De-Escalation of Antipseudomonal Beta-Lactam Antimicrobial Therapy in Enterobacterales Bloodstream Infection
  5. WHO global research priorities for antimicrobial resistance in human health
  6. Incidence and predictors of complications in Gram-negative bloodstream infection
  7. Evaluation of the diagnostic utility of metagenomic next-generation sequencing testing for pathogen identification in infected hosts: a retrospective cohort study
  8. The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States
  9. 750. Launching the South Carolina Regional Infection Prevention Training (SCRIPT) Center: A Pilot in Interprofessional Education
  10. 2763. Evaluating the Safety and Effectiveness of Long-term Antibiotic Suppression in Patients with Left Ventricular Assist Devices
  11. 2399. Changing Demographics of Infective Endocarditis in South Carolina: An Ecological Study
  12. Application of Precision Medicine Concepts in Ambulatory Antibiotic Management of Acute Pyelonephritis
  13. Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action
  14. Interventions in the management of diabetes‐related foot infections: A systematic review
  15. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023)
  16. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes‐related foot infections (IWGDF/IDSA 2023)
  17. Diagnosis of infection in the foot of patients with diabetes: A systematic review
  18. Intravenous versus Partial Oral Antibiotic Therapy in the Treatment of Uncomplicated Bloodstream Infection Due to Streptococcus Species
  19. Optimization of Empirical Antimicrobial Therapy in Enterobacterales Bloodstream Infection Using the Extended-Spectrum Beta-Lactamase Prediction Score
  20. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation
  21. Ecologic analysis of antimicrobial use in South Carolina hospitals during 2020–2022
  22. Epidemiology, Outcomes and Tolerability of Protracted Treatment of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States
  23. Paradoxical outcomes of gram‐negative bloodstream infection in solid organ transplant recipients
  24. The progression of sepsis from physiologic systemic inflammatory response to immune dysregulation due to life-threatening infections
  25. Weighing the odds of Bloodstream Infection. What is the Perfect Model to Predict this Risk?
  26. Temporal Association between Influenza Vaccination Coverage and Ambulatory Antibiotic Use in Children
  27. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey
  28. Evaluation of early clinical failure criteria in Enterococcus species bloodstream infection
  29. Show me the data: A statewide comparative report of National Healthcare Safety Network (NHSN) Antimicrobial Use Option standardized antimicrobial administration ratios (SAARs)
  30. Candida parapsilosis bloodstream infection in an immunocompromised host with discordant multiplex polymerase chain reaction and conventional blood culture results: a case report
  31. Clinical Utility and Cost Effectiveness of Long-Acting Lipoglycopeptides Used in Deep-Seated Infections among Patients with Social and Economic Barriers to Care
  32. Prediction of Mortality in Staphylococcus aureus Bloodstream Infection using Quick Pitt Bacteremia Score
  33. 44. Cost Effectiveness and Clinical Outcomes of Long Acting Lipoglycopeptides Used in Transitions of Care for Deep-Seated Infections
  34. 1298. Validation of Local Pseudomonas aeruginosa Risk Factors in Patients with Community-Onset Bacterial Pneumonia
  35. 1388. Epidemiology and Treatment Outcomes of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States
  36. Change in Antimicrobial Use during COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study
  37. A pandemic recap: lessons we have learned
  38. Impact of follow up blood cultures on outcomes of patients with community-onset gram-negative bloodstream infection
  39. Application of Standardized Antimicrobial Administration Ratio as a Motivational Tool within a Multi-Hospital Healthcare System
  40. Novel method of calculating adjusted antibiotic use by microbiological burden
  41. Risk and Clinical Outcomes of Acute Myocardial Infarction and Acute Ischemic Stroke following Gram-Negative Bloodstream Infection
  42. Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy
  43. Clostridioides difficile infection and antibiotic prescription rates in the community: Explaining the gender gap
  44. Motivational Application of Standardized Antimicrobial Administration Ratios Within a Healthcare System
  45. 243. Temporal Trends in Appropriateness of Ambulatory Antibiotic Prescribing in South Carolina
  46. 290. Impact of follow up blood cultures on outcomes of patients with gram-negative bloodstream infections
  47. 313. Using a Clinical Decision Prediction Tool to Improve Empirical Antimicrobial Therapy in Ceftriaxone-Resistant Enterobacterales Bloodstream Infections
  48. 955. Addressing Gaps and Disparities in HIV testing in the Emergency Department
  49. Regulatory Approval, Implementation, and Brief Assessment of a Pharmacist- and Pharmacy Trainee-Administered Penicillin Allergy Assessment and Skin Testing Program
  50. Use of Antibiotics in Chronic Obstructive Pulmonary Disease: What is Their Current Role in Older Patients?
  51. Regional and statewide antibiograms as targeted interventions against antibiotic resistance
  52. Temporal trends in ambulatory antibiotic prescription rates in South Carolina: Impact of age, gender, and resident location
  53. Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia, and Citrobacter Species
  54. Pharmacist-Driven Culture and Sexually Transmitted Infection Testing Follow-Up Program in the Emergency Department
  55. Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates
  56. Gram-Negative Bacteria with Difficult-to-Treat Resistance: A Moving Target
  57. RISK OF ACUTE MYOCARDIAL INFARCTIONS AND ACUTE ISCHEMIC STROKES FOLLOWING GRAM-NEGATIVE BLOODSTREAM INFECTIONS
  58. Evaluating appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain reaction gastrointestinal testing within a hospital system
  59. Empirical Fluoroquinolones versus Broad-Spectrum Beta-Lactams for Gram-Negative Bloodstream Infections in the Absence of Antimicrobial Resistance Risk Factors
  60. Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study
  61. Prediction of Sulfamethoxazole/Trimethoprim Resistance in Community-Onset Urinary Tract Infections
  62. Erratum
  63. 2733. Association Between Influenza Vaccination Coverage and Ambulatory Antibiotic Prescription Rates in Children in South Carolina
  64. 122. Evaluation of Early Clinical Failure Criteria in Patients with Enterococcus Species Bloodstream Infection
  65. 851. Validation of Quick Pitt Bacteremia Score in Patients with Staphylococcus aureus Bloodstream Infection
  66. Direct Measurement of Performance: A New Era in Antimicrobial Stewardship
  67. COPD Exacerbations — A Target for Antibiotic Stewardship
  68. Seasonal variation in antimicrobial resistance rates of community-acquired Escherichia coli bloodstream isolates
  69. Resilience of the Pitt Bacteremia Score: Three Decades and Counting
  70. Syndrome-specific versus prospective audit and feedback interventions for reducing use of broad-spectrum antimicrobial agents
  71. Oral antibiotics for uncomplicated and complicated bloodstream infections
  72. Evaluation of early clinical failure criteria for gram-negative bloodstream infections
  73. A Baker’s Dozen of Top Antimicrobial Stewardship Publications in 2016
  74. Association Between Body Mass Index and Mortality in Patients With Gram-Negative Bloodstream Infections
  75. Derivation of a quick Pitt bacteremia score to predict mortality in patients with Gram-negative bloodstream infection
  76. Utility of Combination Antimicrobial Therapy in Adults with Bloodstream Infections due to Enterobacteriaceae and Non-Fermenting Gram-Negative Bacilli Based on In Vitro Analysis at Two Community Hospitals
  77. 645
  78. Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible Escherichia coli: A Missed Opportunity for De-Escalation of Therapy
  79. 475. Burden of Clostridium difficile Infection in South Carolina: A Population-Based Study
  80. 1043. Evaluation of Early Clinical Failure Criteria for Gram-Negative Bloodstream Infections
  81. 975. Clostridium difficile Infection and Antibiotic Prescription Rates in the Community: Explaining the Gender Gap
  82. Early de-escalation of antimicrobial therapy reduces risk of C. difficile infection
  83. Minimum Acceptable Susceptibility of Empirical Antibiotic Regimens for Gram-Negative Bloodstream Infections
  84. Ignoring the Elephant: Does the Infectious Diseases Society of America Support Sepsis-3 or Pre-sepsis Criteria?
  85. Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case–case–control study
  86. Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection
  87. Duration of Antimicrobial Therapy for Enterobacteriaceae Bacteremia: Using Convenient End Points for Convenient Conclusions
  88. Got penicillin allergy? Carbapenems are not the answer
  89. A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway
  90. Combination antimicrobial therapy for gram-negative bloodstream infections?
  91. Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
  92. The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey
  93. Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence
  94. The Magic Formula: Optimizing Care While Using Less Broad-Spectrum Antibiotics
  95. For Bloodstream Infections: Optimize, Do Not Minimize
  96. Prediction of fluoroquinolone resistance in patients with complicated urinary tract infections
  97. When to use empirical anti-pseudomonal therapy?
  98. Microbiologic Predictors of Pelvic Osteomyelitis Related to Decubitus Ulcers
  99. Microbiology of Vertebral Osteomyelitis and Implications on Empiric Therapy
  100. A Simplified Pitt Bacteremia Score (qPitt) to Predict Mortality in Patients with Gram-negative Bloodstream Infection
  101. The ESBL Prediction Score
  102. Non-tuberculous mycobacterial bloodstream infections in patients with indwelling vascular catheters – the role of sickle cell anaemia
  103. Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae
  104. Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections
  105. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis
  106. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
  107. Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli
  108. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections
  109. Validation of Fluoroquinolone Resistance Score in Patients With Complicated Urinary Tract Infections
  110. Optimal Duration of Antimicrobial Therapy for Bloodstream Infections Due to Gram-Negative Bacilli
  111. Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization
  112. Osteomyelitis After Open Fractures Adjusting Prophylactic Antimicrobial Therapy
  113. Effectiveness of Oral Antibiotics for Definitive Therapy of Gram-Negative Bloodstream Infections
  114. Prediction of Fluoroquinolone Resistance in Patients With Gram-Negative Bloodstream Infection
  115. Combination Versus Monotherapy for Gram-Negative Bloodstream Infections: Matching by Predicted Prognosis
  116. Association Between Inappropriate Empirical Antimicrobial Therapy and Hospital Length of Stay in Gram-Negative Bloodstream Infections
  117. Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle for Local Management of Gram-Negative Bloodstream Infections
  118. Bloodstream Infections and Central Line–Associated Bloodstream Infections
  119. Antibiotics save lives
  120. External validation of bloodstream infection mortality risk score in a population-based cohort
  121. 715Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
  122. 225Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence
  123. 1705Non-Tuberculous Mycobacterial Bloodstream Infections in Patients with In-Dwelling Vascular Access Catheters- Role of Sickle Cell Disease
  124. Community-acquired Methicillin-resistant Staphylococcus aureus Prostatic Abscesses
  125. Predictive scoring model of mortality in Gram-negative bloodstream infection
  126. Asthma and risk of non-respiratory tract infection: a population-based case–control study
  127. Temporal Trends, Clinical Characteristics, and Outcomes of Histoplasmosis in a Tertiary Care Center in Kentucky, 2000 to 2009
  128. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe
  129. Asthma and Risk of Community-Acquired Blood Stream Infection Caused by Escherichia Coli: A Population-Based Case-Control Study
  130. Asthma and Severity of Blood Stream Infection Caused by Escherichia coli: A Population-Based Study
  131. Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study
  132. Impact of Gram-Negative Bloodstream Infection on Long-Term Allograft Survival After Kidney Transplantation
  133. Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998–2007
  134. Cefepime effectiveness in Gram-negative bloodstream infections
  135. Influence of referral bias on the clinical characteristics of patients with Gram-negative bloodstream infection
  136. Epidemiology and outcome of Gram-negative bloodstream infection in children: a population-based study
  137. Recurrent gram-negative bloodstream infection: A 10-year population-based cohort study
  138. Bacteremia complicating gram-negative urinary tract infections: A population-based study
  139. Epidemiology and Outcome of Klebsiella Species Bloodstream Infection: A Population-Based Study
  140. Are E. coli infections more common in the summer?
  141. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007
  142. Incidence Rate and Outcome of Gram-Negative Bloodstream Infection in Solid Organ Transplant Recipients
  143. β-Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused by Gram-Negative Bacilli
  144. Incidence of Pseudomonas aeruginosa Bacteremia: A Population-Based Study
  145. Invasive Enteric Infections in Hospitalized Patients With Underlying Strongyloidiasis